Study finds skin cancer vaccine reduces recurrence by 50%
OAN’s Abril Elfi
1:38 PM – Tuesday, December 26, 2023
Exciting News: Moderna and Merck Announce Promising Vaccine for Deadliest Skin Cancer
This month, Moderna revealed their groundbreaking vaccine that has shown promising results in clinical trials.
According to a statement from Hackensack Meridian John Theurer Cancer Center in New Jersey, the vaccine has led to a “statistically significant improvement in survival before the cancer returned” for 157 patients with advanced melanoma.
The vaccine utilizes an immunotherapy drug called Keytruda.
Doctor Marc Siegel, a clinical professor of medicine at NYU Langone Medical Center, believes this could be a game changer.
“Keytruda is a checkpoint inhibitor, meaning it blocks an enzyme that the cancer cell uses to become invisible to the immune system,” explained Dr. Marc Siegel. “Keytruda works well in certain kinds of highly mutagenic cancers, including melanoma, and there is often a very effective response, but the cancer can then mutate away from the impact of the drug and once again become resistant to an immune response.”
According to the companies, patients who received the experimental mRNA vaccine in addition to Keytruda experienced a 44% decrease in the chance of death or recurrent disease. These patients had all undergone surgery to remove their cancer.
Doctor Andrew Pecora, an oncologist and researcher at the Hackensack Meridian John Theurer Cancer Center, who has been involved in the clinical trials since the beginning, stated that immunotherapy has been effective in about half of cancer patients. However, for the other half, the tumor proteins are not properly presented to the immune system for recognition and elimination.
The vaccine is personalized to each patient’s tumor, with scientists analyzing a portion of the tumor to identify the mutated DNA and target those specific changes.
No side effects have been reported by the participants, and the vaccine is now entering phase three of the trials.
According to the Melanoma Research Foundation, it was estimated that nearly 187,000 Americans would be diagnosed with melanoma in 2023, with 7,990 expected to die from it.
Stay informed! Subscribe here to receive breaking news blasts directly to your inbox for free: https://www.oann.com/alerts
The U.S. forms a coalition to combat Houthi attacks on shipping in the Red Sea, despite facing resistance from the international community.
Shocking Remarks by North Dakota Representative Nico Rios Caught on Camera During DUI Arrest
The Year 2023: Unprecedented in American Politics, All Centered Around Donald Trump
High Profile Referenda Expected in Several States During the 2024 Elections
Chinese Regulators Announce New Rules Aimed at Various Sectors
Tesla Faces Bottleneck in Battery Production for Cybertruck Due to Speed Constraints
Group of Nonfiction Authors Sue OpenAI and Microsoft for Misuse of Their Books
Tesla Contacted by San Francisco Police Regarding Alleged Stalker’s Remote Access to Vehicle
rnrn
What steps will be taken to further research and validate the efficacy and safety of the mRNA vaccine for melanoma treatment
D proteins. This information is used to create a customized messenger RNA (mRNA) vaccine that targets the specific mutations in the tumor.
The results of the clinical trial are promising, showing that the combination of the mRNA vaccine and Keytruda can significantly improve outcomes for patients with advanced melanoma. The vaccine helps to activate the immune system and enhance its ability to recognize and eliminate cancer cells.
Dr. Pecora explains that the personalized nature of the vaccine makes it particularly effective. By targeting the specific mutations in each patient’s tumor, the vaccine can better activate the immune system’s response. This personalized approach has the potential to revolutionize cancer treatment and improve outcomes for patients.
The groundbreaking vaccine is a collaboration between Moderna, a biotechnology company, and Merck, a pharmaceutical company. The two companies have combined their expertise in mRNA technology and immunotherapy to develop this innovative treatment.
Melanoma is one of the deadliest forms of skin cancer, with a high mortality rate. Current treatment options for advanced melanoma have limitations, and there is a need for more effective therapies. The development of this vaccine represents a significant step forward in the fight against melanoma and offers hope for patients and their families.
While the results of the clinical trial are promising, further research and validation are needed to fully understand the efficacy and safety of the vaccine. The vaccine will undergo additional testing in larger clinical trials to gather more data and gain regulatory approval.
In conclusion, Moderna and Merck’s announcement of a promising vaccine for the deadliest skin cancer, melanoma, brings hope to patients and the medical community. The combination of the personalized mRNA vaccine and immunotherapy drug Keytruda has shown significant improvements in patient outcomes. This breakthrough treatment has the potential to revolutionize cancer therapy and improve survival rates for advanced melanoma patients. Additional research and clinical trials will be conducted to further validate the vaccine’s efficacy and ensure its safety.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
Now loading...